Isthmus Partners LLC Trims Holdings in MiMedx Group, Inc. (NASDAQ:MDXG)

Isthmus Partners LLC reduced its position in MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) by 22.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 306,413 shares of the company's stock after selling 86,801 shares during the quarter. Isthmus Partners LLC owned about 0.21% of MiMedx Group worth $1,811,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. Price T Rowe Associates Inc. MD raised its holdings in shares of MiMedx Group by 13.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 32,978 shares of the company's stock worth $254,000 after purchasing an additional 3,806 shares during the period. Harbor Capital Advisors Inc. acquired a new position in MiMedx Group during the second quarter valued at approximately $1,781,000. Bank of New York Mellon Corp lifted its position in MiMedx Group by 9.4% during the second quarter. Bank of New York Mellon Corp now owns 409,344 shares of the company's stock valued at $2,837,000 after buying an additional 35,107 shares in the last quarter. Allspring Global Investments Holdings LLC grew its stake in MiMedx Group by 9.2% during the second quarter. Allspring Global Investments Holdings LLC now owns 181,199 shares of the company's stock worth $1,256,000 after buying an additional 15,240 shares during the period. Finally, Cannon Global Investment Management LLC acquired a new stake in shares of MiMedx Group in the second quarter worth $118,000. 79.15% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

MDXG has been the subject of a number of research reports. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $11.00 price target on shares of MiMedx Group in a research report on Thursday, August 1st. StockNews.com downgraded MiMedx Group from a "strong-buy" rating to a "buy" rating in a research report on Friday, November 8th. Finally, Craig Hallum lowered their target price on MiMedx Group from $14.00 to $12.00 and set a "buy" rating for the company in a research note on Thursday, August 1st. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, MiMedx Group has a consensus rating of "Buy" and an average price target of $12.00.

MiMedx Group Stock Down 1.9 %

MDXG stock traded down $0.18 during trading on Friday, reaching $9.25. The stock had a trading volume of 525,241 shares, compared to its average volume of 747,592. The firm has a fifty day moving average price of $6.91 and a 200 day moving average price of $6.91. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10. The company has a market capitalization of $1.36 billion, a P/E ratio of 16.82 and a beta of 1.94. MiMedx Group, Inc. has a 1-year low of $5.47 and a 1-year high of $9.64.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.